Restorative gene editing using sequences from the counterpart chromosome: The standard CRISPR enzyme Cas9 offers the ability to make repairs but also potentially results in unintended mutations (mutagenic events) at the targeted site and possibly elsewhere in the genome (left). In contrast, the nickase enzyme results in more efficient gene correction and no mutagenic events (right).
Targeted repairs with ‘nicks’ of single DNA strands provide foundation for novel disease therapies
Curing debilitating genetic diseases is one of the great challenges of modern medicine. During the past decade, development of CRISPR technologies and advancements in genetics research brought new hope for patients and their families, although the safety of these new methods is still of significant concern.
Publishing July 1 in the journal Science Advances, a team of biologists at the University of California San Diego that includes postdoctoral scholar Sitara Roy, specialist Annabel Guichard and Professor Ethan Bier describes a new, safer approach that may correct genetic defects in the future. Their strategy, which makes use of natural DNA repair machinery, provides a foundation for novel gene therapy strategies with the potential to cure a large spectrum of genetic diseases.
In many cases, those suffering from genetic disorders carry distinct mutations in the two copies of genes inherited from their parents. This means that often, a mutation on one chromosome will have a functional sequence counterpart on the other chromosome. The researchers employed CRISPR genetic editing tools to exploit this fact.
“The healthy variant can be used by the cell’s repair machinery to correct the defective mutation after cutting the mutant DNA,” said Guichard, the senior author of the study, “Remarkably, this can be achieved even more efficiently by a simple harmless nick.”
Working in fruit flies, the researchers designed mutants permitting visualization of such “homologous chromosome-templated repair,” or HTR, by the production of pigments in their eyes. Such mutants initially featured entirely white eyes. But when the same flies expressed CRISPR components (a guide RNA plus Cas9), they displayed large red patches across their eyes, a sign that the cell’s DNA repair machinery had succeeded in reversing the mutation using the functional DNA from the other chromosome.
They then tested their new system with Cas9 variants known as “nickases” that targeted just one strand of DNA instead of both. Surprisingly, the authors found that such nicks also gave rise to high-level restoration of red eye color nearly on par with normal (non-mutated) healthy flies. They found a 50-70% repair success rate with the nickase compared with just 20-30% in dual-strand cutting Cas9, which also generates frequent mutations and targets other sites throughout the genome (so-called off-target mutations). “I could not believe how well the nickase worked—it was completely unanticipated,” said Roy, the lead author of the study. The versatility of the new system could serve as a model for fixing genetic mutations in mammals, the researchers noted.
“We don’t know yet how this process will translate to human cells and if we can apply it to any gene,” said Guichard. “Some adjustment may be needed to obtain efficient HTR for disease-causing mutations carried by human chromosomes.”
The new research extends the group’s previous achievements in precision-editing with “allelic-drives,” which expand on principles of gene-drives with a guide RNA that directs the CRISPR system to cut undesired variants of a gene and replace them with a preferred version of the gene.
A key feature of the team’s research is that their nickase-based system causes far fewer on- and off-target mutations, as is known to happen with more traditional Cas9-based CRISPR edits. They also say a slow, continuous delivery of nickase components across several days may prove more beneficial than one-time deliveries.
“Another notable advantage of this approach is its simplicity,” said Bier. “It relies on very few components and DNA nicks are ‘soft,’ unlike Cas9, which produces full DNA breaks often accompanied by mutations.”
“If the frequency of such events could be increased either by promoting interhomolog pairing or by optimizing nick-specific repair processes, such strategies could be harnessed to correct numerous dominant or trans-heterozygous disease-causing mutations,” said Roy.
Original Article: “Soft” CRISPR May Offer a New Fix for Genetic Defects
More from: University of California San Diego
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nickase-based system
- BAE Systems wins $365 million contract to build geostationary weather instrument
BAE Systems, the former Ball Aerospace and Technologies Corp., won a $365 million contract May 1 to develop an air quality sensor for a U.S. geostationary weather satellites.
- BAE Systems Tasked by NASA to Develop a New Instrument for Air Quality Monitoring for NOAA’s Satellite Program
On behalf of the National Oceanic and Atmospheric Administration (NOAA), NASA has entrusted BAE Systems, formerly known as Ball Aerospace & Technologies Corporation, based in Boulder, Colorado, with ...
- Next-Generation Space-Based Missile Warning Capability Passes Critical Design Review
The Next Generation Overhead Persistent Infrared Polar, or OPIR NGP, program has cleared its space vehicle critical design review, an important milestone in the development of the space-based global ...
- LLM-Based Data Loss Prevention Is Dope Security
Dope.security's CASB Neural is a new solution that uses LLMs to deliver an innovative CASB tool that enhances the security and management of SaaS applications.
- Defending infrastructure, securing systems key to CISA’s new AI guidelines
The guidelines are part of Homeland Security’s ongoing efforts to reduce the risks, and maximize the benefits of artificial intelligence.
Go deeper with Google Headlines on:
Nickase-based system
[google_news title=”” keyword=”nickase-based system” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Novel gene therapy strategies
- A New Delivery System Offers Hope for Cystic Fibrosis
CRISPR-carrying lipid nanoparticles enabled researchers to correct a rare nonsense mutation in the lungs of a cystic fibrosis mouse model.
- ADVM Adverum Biotechnologies, Inc.
The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies ...
- OSU researchers pioneer technique for delivering gene therapy to specific brain areas
Researchers say the procedure holds promise for a host of genetic neurological disorders, including Parkinson's, Alzheimer's, multiple system atrophy (ASA) and more.
- Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
However, the company has several clinical-stage, novel gene therapy candidates in its pipeline, which are being developed for various ophthalmologic indications. The focus, consequently ...
- RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers
April 23, 2024--(BUSINESS WIRE)--RootPath, a synthetic biology company that elevates the throughput of gene ... novel gene synthesis technology and how it may contribute to successful cell therapy ...
Go deeper with Google Headlines on:
Novel gene therapy strategies
[google_news title=”” keyword=”novel gene therapy strategies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]